Literature DB >> 23986257

PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients.

Yawei Liu1, Robert Carlsson, Malene Ambjørn, Maruf Hasan, Wiaam Badn, Anna Darabi, Peter Siesjö, Shohreh Issazadeh-Navikas.   

Abstract

Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor. In general, tumor growth requires disruption of the tissue microenvironment, yet how this affects glioma progression is unknown. We studied program death-ligand (PD-L)1 in neurons and gliomas in tumors from GBM patients and associated the findings with clinical outcome. Remarkably, we found that upregulation of PD-L1 by neurons in tumor-adjacent brain tissue (TABT) associated positively with GBM patient survival, whereas lack of neuronal PD-L1 expression was associated with high PD-L1 in tumors and unfavorable prognosis. To understand the molecular mechanism of PD-L1 signaling in neurons, we investigated PD-L1 function in cerebellar and cortical neurons and its impact on gliomas. We discovered that neuronal PD-L1-induced caspase-dependent apoptosis of glioma cells. Because interferon (IFN)-β induces PD-L1 expression, we studied the functional consequences of neuronal Ifnb gene deletion on PD-L1 signaling and function. Ifnb-/- neurons lacked PD-L1 and were defective in inducing glioma cell death; this effect was reversed on PD-L1 gene transfection. Ifnb-/- mice with intracerebral isografts survived poorly. Similar to the observations in GBM patients, better survival in wild-type mice was associated with high neuronal PD-L1 in TABT and downregulation of PD-L1 in tumors, which was defective in Ifnb-/- mice. Our data indicated that neuronal PD-L1 signaling in brain cells was important for GBM patient survival. Reciprocal PD-L1 regulation in TABT and tumor tissue could be a prognostic biomarker for GBM. Understanding the complex interactions between tumor and adjacent stromal tissue is important in designing targeted GBM therapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23986257      PMCID: PMC6618508          DOI: 10.1523/JNEUROSCI.5812-12.2013

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  64 in total

1.  Neuro-oncology: Glioblastoma prognosis linked to neuronal PD-L1 expression in tumour-adjacent tissue.

Authors:  Katie Kingwell
Journal:  Nat Rev Neurol       Date:  2013-09-17       Impact factor: 42.937

2.  B7-H1 agonists could prevent disseminated inflammation by desensitizing cell susceptibility to cytotoxic T-cells.

Authors:  Weiwei Yu; Ling Chen; Sizheng Guo; Liqun Luo; Lieping Chen
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

3.  MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.

Authors:  Jun Wei; Edjah K Nduom; Ling-Yuan Kong; Yuuri Hashimoto; Shuo Xu; Konrad Gabrusiewicz; Xiaoyang Ling; Neal Huang; Wei Qiao; Shouhao Zhou; Cristina Ivan; Greg N Fuller; Mark R Gilbert; Willem Overwijk; George A Calin; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2015-12-11       Impact factor: 12.300

4.  Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.

Authors:  Tsubasa Miyazaki; Eiichi Ishikawa; Masahide Matsuda; Hiroyoshi Akutsu; Satoru Osuka; Noriaki Sakamoto; Shingo Takano; Tetsuya Yamamoto; Koji Tsuboi; Akira Matsumura
Journal:  J Neurooncol       Date:  2017-04-26       Impact factor: 4.130

5.  Imbalance of immunological synapse-kinapse states reflects tumor escape to immunity in glioblastoma.

Authors:  Laura R Díaz; Elena Saavedra-López; Leire Romarate; Izaskun Mitxitorena; Paola V Casanova; George P Cribaro; José M Gallego; Ana Pérez-Vallés; Jerónimo Forteza-Vila; Clara Alfaro-Cervello; José M García-Verdugo; Carlos Barcia; Carlos Barcia
Journal:  JCI Insight       Date:  2018-09-20

Review 6.  Immunosuppressive mechanisms in glioblastoma.

Authors:  Edjah K Nduom; Michael Weller; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 7.  Recent advances and future of immunotherapy for glioblastoma.

Authors:  Neha Kamran; Alexandra Calinescu; Marianela Candolfi; Mayuri Chandran; Yohei Mineharu; Antonela S Asad; Carl Koschmann; Felipe J Nunez; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2016-07-27       Impact factor: 4.388

Review 8.  Immunotherapy for brain cancer: recent progress and future promise.

Authors:  Christopher M Jackson; Michael Lim; Charles G Drake
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

9.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Authors:  Chih-Hao Chang; Jing Qiu; David O'Sullivan; Michael D Buck; Takuro Noguchi; Jonathan D Curtis; Qiongyu Chen; Mariel Gindin; Matthew M Gubin; Gerritje J W van der Windt; Elena Tonc; Robert D Schreiber; Edward J Pearce; Erika L Pearce
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

10.  PD-L1 expression and prognostic impact in glioblastoma.

Authors:  Edjah K Nduom; Jun Wei; Nasser K Yaghi; Neal Huang; Ling-Yuan Kong; Konrad Gabrusiewicz; Xiaoyang Ling; Shouhao Zhou; Cristina Ivan; Jie Qing Chen; Jared K Burks; Greg N Fuller; George A Calin; Charles A Conrad; Caitlin Creasy; Krit Ritthipichai; Laszlo Radvanyi; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2015-08-30       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.